Aripiprazole Tablet
Product Images NDC 68788-7063

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-7063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazoletablets 20mg (Image Containerlabel 20)

This is a medication description for Aripiprazole Tablets 20mg, which is the generic version of Abilify. Each tablet contains 20mg of arpiprazole, and it is manufactured by Torrent Pharmaceuticals Limited. The instructions for use are not available in the text, but there is a cautionary statement that federal law prohibits the transfer of this drug to anyone other than the patient for whom it was prescribed. The rest of the text is mostly product and manufacturing information such as production number, lot number, and NDC number.*

FDA Label Image

Image 1 (Image Fig1 Effectofotherdrug Arip)

FDA Label Image

Image 2 (Image Fig2 Effectofotherdrug Dehydroarip)

Figure 2 shows the impact of other drugs on the pharmacokinetics of Dehydro-Aripiprazole. The fold change and its 90% confidence interval of Dehydro-Aripiprazole is displayed. The effects of drugs such as Cypaps, aundne, a, Pt, et, gastric beckars, oner, and ariose are represented in the chart. There is also a percentage change relative to the reference shown.*

FDA Label Image

Image 3 (Image Fig3 Effectofarip Otherdrug)

This is a table that shows the effect of aripiprazole on the pharmacokinetics of various other drugs. The table shows different drugs such as deropmetoptan, cvpace, artann, omeprazole, lamotigine, valproate, lithium, lorazepam, venidaine, odesmyhenataing, and escitiopram and their fold change and 50% CI when administered with aripiprazole. The table also shows the change relative to reference (without interacting drug) and different percentages from 5 to 30.*

FDA Label Image

Image 4 (Image Fig4 Effectofintrinsicfactor Arip)

The text describes the effects of intrinsic factors on the pharmacokinetics of the drug aripiprazole. The text includes information on the fold change and 90% confidence interval of the drug in special populations based on factors such as metabolism, gender, hepatic impairment, and renal impairment. The text provides graphs displaying the change relative to reference of the drug in various populations.*

FDA Label Image

Image 5 (Image Fig5 Effectofintrinsicfactor Dehydroarip)

This is a table showing the effects of different intrinsic factors on the pharmacokinetics of dehydro-aripiprazole. The factors evaluated include CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment. The table shows the fold change and confidence interval for AUC and Cmax at different levels of each factor compared to a reference.*

FDA Label Image

Fig 6 (Image Fig6 Schizophreniastudy 5)

This is a graph (Figure 6) of the Kaplan-Meier estimation of cumulative proportion of patients with relapse for Schizophrenia Study 5. The graph compares the results of Aripiprazole and Placebo. The X-axis represents the number of days from randomization, and the Y-axis represents the cumulative proportion of patients with relapse. The graph also includes a table showing the number of subjects at risk for each treatment arm. This information could be useful to analyze the effectiveness of Aripiprazole in reducing relapse in patients with schizophrenia.*

FDA Label Image

7 (Image Fig7 Bipolarstudy 7)

This is a statistical analysis of a bipolar study, with Figure 7 presenting the Kaplan-Meier Estimation of the cumulative proportion of patients with relapse. The graph compares the results of the study for Aripiprazole against Placebo over the course of several days from randomization. The graph shows the reduction in the number of subjects at risk over time for each drug.*

FDA Label Image

8 (Image Fig8 Bipolarstudy 8)

This is a graph (Figure 8) that shows the Kaplan-Meier Estimation of the cumulative proportion of patients who have relapsed to any mood event in a bipolar study (Bipolar Study 8). The x-axis indicates the number of days from randomization, and the y-axis shows the proportion with relapse. The data points represent two treatment groups: ABILIFY (168 patients) and LACE 169 (77 patients).*

FDA Label Image

9 (Image Fig9 Tourettesdisorderstudy1)

This is a graph showing the least square means of change in YGTSS TTS by week for Tourette's Disorder Study 1. The text also includes a table of values for the change in YGTSS total tic score from baseline, categorized by weeks of treatment. Therefore, the text provides data on the effectiveness of treatment on reducing tics in Tourette's disorder.*

FDA Label Image

Image (Image Logo Medguide)

FDA Label Image

Logo (Image Logo Pi)

FDA Label Image

Description Image (Image Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.